BIOMAT Database Logo BIOMAT Database Logo

Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. 2012

Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Department of Leukemia, Division of Cancer Medicine, The University of Texas: MD Anderson Cancer Center, Houston, USA. ejabbour@mdanderson.org

Dramatically improved survival associated with tyrosine kinase inhibitor (TKI) therapy has transformed the disease model for chronic myeloid leukemia (CML) to one of long-term management, but treatment success is challenged with poor medication adherence. Many risk factors associated with poor adherence can be ameliorated by close monitoring, dose modification, and supportive care. Controlling risk factors for poor adherence in combination with patient education that includes direct communication between the health care team and the patient are essential components for maximizing the benefits of TKI therapy.

UI MeSH Term Description Entries
D010353 Patient Education as Topic The teaching or training of patients concerning their own health needs. Education of Patients,Education, Patient,Patient Education
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001549 Benzamides BENZOIC ACID amides.
D015466 Leukemia, Myeloid, Chronic-Phase The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase. Granulocytic Leukemia, Chronic, Stable-Phase,Leukemia, Granulocytic, Chronic-Phase,Leukemia, Myelogenous, Chronic-Phase,Leukemia, Myeloid, Stable-Phase,Myelogenous Leukemia, Chronic, Chronic-Phase,Myeloid Leukemia, Chronic, Chronic-Phase,Myeloid Leukemia, Chronic, Stable-Phase,Granulocytic Leukemia, Chronic, Stable Phase,Leukemia, Granulocytic, Chronic Phase,Leukemia, Myelogenous, Chronic Phase,Leukemia, Myeloid, Chronic Phase,Leukemia, Myeloid, Stable Phase,Myelogenous Leukemia, Chronic, Chronic Phase,Myeloid Leukemia, Chronic, Chronic Phase
D016527 Drug Costs The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES). Cost, Drug,Costs, Drug,Drug Cost

Related Publications

Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
[Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
January 2013, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
July 2012, Leukemia research,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
November 2021, The Korean journal of internal medicine,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
April 2009, Cancer control : journal of the Moffitt Cancer Center,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
January 2013, Acta haematologica,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy.
April 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.
October 2012, Blood cancer journal,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia.
March 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia.
November 2023, International immunopharmacology,
Elias J Jabbour, and Hagop Kantarjian, and Lina Eliasson, and A Megan Cornelison, and David Marin
Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.
March 2021, Leukemia & lymphoma,
Copied contents to your clipboard!